Calidi Biotherapeutics, Inc. CLDI

Calidi Biotherapeutics received a notice from NYSE American stating the company is not in compliance with continued listing standards due to stockholders' equity below $4.0 million after losses in three of the last four fiscal years. No exemption applies. The company must submit a plan by October 21, 2026 outlining actions to regain compliance by March 21, 2028; if accepted, it will be subject to quarterly monitoring. If not, delisting proceedings will begin, and even with an accepted plan failure to regain compliance or progress could trigger delisting. There is no immediate effect on trading, but shares will trade under CLDI with an appended designation .BC indicating below-compliance. Management says it is evaluating options and intends to file a plan by the deadline. The report also notes Calidi's RedTail platform and DLD-401 pipeline. Potential delisting and ongoing monitoring could materially affect liquidity and financing prospects.

Calidi Biotherapeutics reported its second quarter 2026 financial results and recent business highlights. Quarterly financial results and business updates supply performance data that can moderately shift investor sentiment and near-term outlook.

Calidi Biotherapeutics issues mid-year corporate update outlining future key value drivers. Mid-year update with key value drivers signals major strategic developments likely to shift trajectory and sentiment.

Calidi Biotherapeutics presented new data on CLD-501, its in situ T-cell engager candidate targeting TROP-2, at the T-Cell Engager Therapeutic Summit. Data presentation on early-stage pipeline candidate may generate modest investor interest without altering core trajectory.

Calidi Biotherapeutics received positive pre-IND feedback from the US FDA for CLD-401, confirming agreement on its development strategy and advancing toward a first-in-human study. Positive FDA pre-IND feedback directly validates CLD-401 development path and accelerates first-in-human trial progress.

Calidi Biotherapeutics, Inc. (CLDI) reported first quarter 2026 financial results and recent operational highlights. Quarterly financial results and operational highlights moderately influence financial performance and investor sentiment.

Calidi Biotherapeutics (CLDI) announces strategic partnership with TransferAI to utilize agentic AI for driving efficiencies in the IND submission process for its CLD-401 program. Partnership leverages AI to streamline IND submission for CLD-401, potentially accelerating regulatory timelines and clinical development without fundamentally transforming the company's position.

Calidi Biotherapeutics presented new data on its lead asset CLD-401 at the AACR Annual Meeting in April 2026. Presentation of new data on lead oncology asset at AACR Annual Meeting represents a major milestone likely to drive investor sentiment and validate pipeline progress.

Calidi Biotherapeutics presented new data on its differentiated in situ T-cell engager platform, including a novel candidate targeting TROP-2, at the AACR Annual Meeting in April 2026. New data and TROP-2 candidate announcement at AACR highlight pipeline expansion in oncology immunotherapy, poised to significantly boost investor sentiment and competitive edge.

Calidi Biotherapeutics will present new data on its lead asset CLD-401 at the AACR Annual Meeting in April 2026. Presentation of new data on lead asset at major oncology conference signals pipeline progress but impact awaits actual data disclosure.

Calidi Biotherapeutics to present new data on its differentiated in situ T-cell engagers approach, including a new TROP-2 targeting candidate, at the AACR Annual Meeting in April 2026. Presentation of new data on innovative T-cell engagers targeting TROP-2 at AACR advances pipeline and competitive positioning but limited by 2026 timeline.

Calidi Biotherapeutics, Inc. (CLDI) reported fourth quarter and full-year 2025 financial results, highlighting recent operational progress. Financial results and operational highlights reveal critical updates on clinical trials, cash position, and strategic advancements impacting stock trajectory.

Calidi Biotherapeutics announces partnership with Avance Clinical to facilitate Australian regulatory approval and accelerate initiation of CLD-401 clinical trials. Partnership expedites regulatory approval and clinical trial start for CLD-401, marking a major strategic advancement in pipeline development.

Calidi Biotherapeutics presented its innovative and scalable manufacturing process for CLD-401 at the 9th Annual Bioprocessing Summit, with FDA feedback supporting the company's approach. FDA endorsement of scalable manufacturing for CLD-401 bolsters production scalability and regulatory pathway, significantly enhancing commercialization prospects.

Calidi Biotherapeutics, Inc. (CLDI) closed a $6.0 million underwritten public offering, with underwriters fully exercising their over-allotment option for additional shares. The $6 million capital infusion bolsters CLDI's balance sheet, enabling continued R&D and operations amid biotech funding needs.

Calidi Biotherapeutics, Inc. (CLDI) priced a $5.2 million underwritten public offering, expecting gross proceeds of $5.2 million before fees and expenses. The $5.2 million public offering provides essential capital for operations but dilutes existing shareholders, significantly impacting financial position and market sentiment.

Calidi Biotherapeutics, Inc. (CLDI) announced a proposed underwritten public offering of its common stock. The offering size and terms remain subject to market conditions and finalization, with proceeds earmarked for general corporate purposes, working capital, and clinical development. Public offerings dilute existing shares and signal cash burn, significantly impacting short-term stock price and long-term capital structure for cash-intensive biotech CLDI.

Calidi Biotherapeutics presented data on its RedTail platform's new approach to Bispecific T-Cell Engagers (BiTEs) at the 2026 AACR-IO Conference. Presentation of data on innovative RedTail BiTE approach at major AACR-IO conference advances oncology pipeline and could significantly boost investor sentiment.

Calidi Biotherapeutics, Inc. (CLDI) will present a late-breaking abstract on its innovative approach to Bispecific T-Cell Engagers (BiTEs) utilizing the RedTail Platform at the 2026 AACR-IO Conference. This presentation highlights the company's advancements in cancer immunotherapy and aims to showcase the potential of its technology in enhancing treatment efficacy. The presentation at a prominent conference indicates a significant strategic move that could enhance investor sentiment and the company's competitive positioning in the biotherapeutics market.

Calidi Biotherapeutics, Inc. provided a corporate update highlighting key value drivers for 2026, focusing on advancements in its proprietary therapies and strategic partnerships aimed at enhancing its market position. The company outlined its goals for product development and potential market expansion, emphasizing the importance of innovation in its therapeutic offerings. Significant strategic moves and advancements in proprietary therapies are expected to alter the company's trajectory and investor sentiment.

Calidi Biotherapeutics, Inc. (CLDI) and Nova Minerals will be featured in interviews on the RedChip Small Stocks, Big Money(TM) Show airing on Bloomberg TV. This exposure aims to highlight their business strategies and growth potential to a broader audience, potentially attracting investor interest. Increased media exposure may enhance investor sentiment and interest in Calidi Biotherapeutics, impacting its market performance moderately.

Calidi Biotherapeutics, Inc. (CLDI) reported its financial results for the third quarter of 2025, highlighting key operational achievements. The company continues to advance its biotherapeutic pipeline, focusing on innovative treatments and strategic partnerships. Financial metrics indicate growth, with increased revenue and reduced losses compared to previous quarters. Management emphasized ongoing research initiatives and potential market opportunities, aiming to enhance shareholder value and expand its market presence. Significant operational highlights and financial improvements suggest a strong potential for future growth and market impact.

Calidi Biotherapeutics, Inc. presented new data on its lead therapeutic, CLD-401, at the 2025 SITC Annual Meeting and held its inaugural Investor Day during the event, highlighting advancements in its clinical development and engaging with investors. The presentation of new data and the Investor Day could significantly enhance investor sentiment and strategic positioning in the market.

Calidi Biotherapeutics, Inc. (CLDI) has announced an investor event scheduled for Friday, November 7th, during the 2025 SITC Annual Meeting. This event aims to provide insights into the company's developments and future plans, potentially engaging current and prospective investors. The investor event may influence market sentiment and provide insights into the company's strategic direction, but its overall impact is expected to be limited.

Calidi Biotherapeutics has partnered with Matica Bio, a leader in oncolytic virus manufacturing, to advance its project toward Investigational New Drug (IND) application. This collaboration aims to enhance the development and production capabilities of Calidi's oncolytic virus therapies, which are designed to target and destroy cancer cells. The partnership is expected to streamline the path to clinical trials and regulatory approval, potentially accelerating the availability of innovative cancer treatments. The partnership with Matica Bio is a significant strategic move that could enhance Calidi's development capabilities and expedite its path to market.

Calidi Biotherapeutics, Inc. (CLDI) announced that new data regarding its therapeutic lead, CLD-401, will be presented at the 2025 SITC Annual Meeting. This presentation is expected to highlight advancements in the treatment's efficacy and safety profile, potentially influencing future research and development strategies. The presentation of new data at a significant conference could lead to increased investor interest and strategic opportunities for the company's product pipeline.

Calidi Biotherapeutics, Inc. has established a Scientific Advisory Board to enhance the development of its CLD-401 product and advance the RedTail platform for systemic delivery of targeted genetic medicine. This initiative aims to leverage expert insights to accelerate innovation and improve therapeutic outcomes. The formation of a Scientific Advisory Board indicates a strategic move that could significantly enhance product development and market positioning.

Calidi Biotherapeutics, Inc. (CLDI) is set to present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston. This event focuses on advancements in oncology and provides a platform for companies to showcase their innovations and potential partnerships in the field. Participation in a prominent oncology summit may enhance visibility and networking opportunities, potentially influencing future collaborations and innovations.

Calidi Biotherapeutics, Inc. (CLDI) announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, where the company will present its innovative biotherapeutic solutions. This event provides a platform for Calidi to engage with investors and showcase its advancements in the field of cancer treatment, potentially enhancing its visibility and investor interest. Participation in a significant investment conference may enhance investor interest and visibility, impacting market sentiment moderately.

Calidi Biotherapeutics, Inc. has successfully closed a $6.9 million underwritten public offering, including the full exercise of the underwriters’ over-allotment option. This funding is expected to support the company's ongoing development efforts and operational needs. The capital raised will provide necessary resources for development, potentially influencing financial performance and market positioning.